Radiotherapy combined with TLR7/8 activation induces strong immune responses against gastrointestinal tumors

Oncotarget

Volumn 6, Issue 7, 2015, Pages 4663-4676

  Schölch, Sebastian ^a,b,c   Rauber, Conrad ^b,c   Tietz, Alexandra ^b,c   Rahbari, Nuh N ^a   Bork, Ulrich ^a   Schmidt, Thomas ^b   Kahlert, Christoph ^a   Haberkorn, Uwe ^b   Tomai, Mark A ^d   Lipson, Kenneth E ^e   Carretero, Rafael ^c   Weitz, Jürgen ^a   Koch, Moritz ^a   Huber, Peter E ^b,c  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d 3M COMPANY   (United States)

^e FIBROGEN INC   (United States)

Author keywords

Colorectal cancer; Immunotherapy; Pancreatic cancer; Radiotherapy; TLR7 8 ligand

Indexed keywords

3M 011; MONOCLONAL ANTIBODY; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; 3M 001; CYTOKINE; IMIDAZOLE DERIVATIVE; QUINOLINE DERIVATIVE; TLR7 PROTEIN, HUMAN; TLR8 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTATION; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER REGRESSION; CARCINOMA CELL LINE; CD8+ T LYMPHOCYTE; CELL ISOLATION; CELL POPULATION; CELL PROLIFERATION; CELL SELECTION; CLINICAL EFFECTIVENESS; COLORECTAL CARCINOMA; CONTROLLED STUDY; CYTOTOXICITY ASSAY; DENDRITIC CELL; DRUG RESPONSE; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; GASTROINTESTINAL TUMOR; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; LYMPH NODE METASTASIS; MOUSE; NATURAL KILLER CELL; NONHUMAN; PANCREAS ADENOCARCINOMA; POSITRON EMISSION TOMOGRAPHY; RADIOIMMUNOTHERAPY; TRANSGENIC MOUSE; AGONISTS; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; COLORECTAL NEOPLASMS; CYTOTOXIC T LYMPHOCYTE; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; ENZYME IMMUNOASSAY; IMMUNOLOGY; IMMUNOTHERAPY; IONIZING RADIATION; METABOLISM; MULTIMODALITY CANCER THERAPY; PANCREATIC NEOPLASMS; RADIATION RESPONSE; TUMOR CELL CULTURE;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; CYTOKINES; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; HUMANS; IMIDAZOLES; IMMUNOENZYME TECHNIQUES; IMMUNOTHERAPY; KILLER CELLS, NATURAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PANCREATIC NEOPLASMS; QUINOLINES; RADIATION, IONIZING; T-LYMPHOCYTES, CYTOTOXIC; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 8; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84924955889     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3081     Document Type: Article

References (36)

1. Weitz J, Koch M, Debus J, Höhler T, Galle PR, Büchler MW. Colorectal cancer. Lancet. 2005;365:153-65.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11-30.
3. Bath-Hextall F, Ozolins M, Armstrong SJ, Colver GB, Perkins W, Miller PSJ, Williams HC, Surgery versus Imiquimod for Nodular Superficial basal cell carcinoma (SINS) study group. Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial. Lancet Oncol. 2014;15:96-105.
4. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol. 2001;2:675-80.
5. Dumitru CD, Antonysamy MA, Gorski KS, Johnson DD, Reddy LG, Lutterman JL, Piri MM, Proksch J, McGurran SM, Egging EA, Cochran FR, Lipson KE, Tomai MA, et al. NK1.1+ cells mediate the antitumor effects of a dual Toll-like receptor 7/8 agonist in the disseminated B16-F10 melanoma model. Cancer Immunol Immunother CII. 2009;58:575-87.
6. Dumitru CD, Antonysamy MA, Tomai MA, Lipson KE. Potentiation of the anti-tumor effects of imidazoquinoline immune response modifiers by cyclophosphamide. Cancer Biol Ther. 2010;10:155-65.
7. Seremet T, Brasseur F, Coulie PG. Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy. Cancer J Sudbury Mass. 2011;17:325-30.
8. Baxevanis CN, Voutsas IF, Tsitsilonis OE. Toll-like receptor agonists: current status and future perspective on their utility as adjuvants in improving anticancer vaccination strategies. Immunotherapy. 2013;5:497-511.
9. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature. 2007;449:419-26.
10. Beignon A-S, McKenna K, Skoberne M, Manches O, DaSilva I, Kavanagh DG, Larsson M, Gorelick RJ, Lifson JD, Bhardwaj N. Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions. J Clin Invest. 2005;115:3265-75.
11. Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst. 2013;105:256-65.
12. Kalbasi A, June CH, Haas N, Vapiwala N. Radiation and immunotherapy: a synergistic combination. J Clin Invest. 2013;123:2756-63.
13. Finkelstein SE, Fishman M. Clinical opportunities in combining immunotherapy with radiation therapy. Front Oncol. 2012;2:169.
14. Rödel F, Frey B, Multhoff G, Gaipl U. Contribution of the immune system to bystander and non-targeted effects of ionizing radiation. Cancer Lett. 2013;
15. Klug F, Prakash H, Huber PE, Seibel T, Bender N, Halama N, Pfirschke C, Voss RH, Timke C, Umansky L, Klapproth K, Schäkel K, Garbi N, et al. Low-dose irradiation programs macrophage differentiation to an iNOS+/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell. 2013;24:589-602.
16. Garbi N, Arnold B, Gordon S, Hämmerling GJ, Ganss R. CpG motifs as proinflammatory factors render autochthonous tumors permissive for infiltration and destruction. J Immunol Baltim Md 1950. 2004;172:5861-9.
17. Ochi A, Graffeo CS, Zambirinis CP, Rehman A, Hackman M, Fallon N, Barilla RM, Henning JR, Jamal M, Rao R, Greco S, Deutsch M, Medina-Zea MV, et al. Toll-like receptor 7 regulates pancreatic carcinogenesis in mice and humans. J Clin Invest. 2012;122:4118-29.
18. Loges S, Schmidt T, Tjwa M, van Geyte K, Lievens D, Lutgens E, Vanhoutte D, Borgel D, Plaisance S, Hoylaerts M, Luttun A, Dewerchin M, Jonckx B, et al. Malignant cells fuel tumor growth by educating infiltrating leukocytes to produce the mitogen Gas6. Blood. 2010;115:2264-73.
19. Moreno M, Mol BM, von Mensdorff-Pouilly S, Verheijen RHM, de Jong EC, von Blomberg BME, van den Eertwegh AJM, Scheper RJ, Bontkes HJ. Differential indirect activation of human invariant natural killer T cells by Toll-like receptor agonists. Immunotherapy. 2009;1:557-70.
20. Luger TA, Krutmann J, Kirnbauer R, Urbanski A, Schwarz T, Klappacher G, Köck A, Micksche M, Malejczyk J, Schauer E. IFN-beta 2/IL-6 augments the activity of human natural killer cells. J Immunol Baltim Md 1950. 1989;143:1206-9.
21. Luger TA, Schwarz T, Krutmann J, Kirnbauer R, Neuner P, Köck A, Urbanski A, Borth W, Schauer E. Interleukin-6 is produced by epidermal cells and plays an important role in the activation of human T-lymphocytes and natural killer cells. Ann N Y Acad Sci. 1989;557:405-14.
22. Wang M, Ellison CA, Gartner JG, HayGlass KT. Natural killer cell depletion fails to influence initial CD4 T cell commitment in vivo in exogenous antigen-stimulated cytokine and antibody responses. J Immunol Baltim Md 1950. 1998;160:1098-105.
23. Kruisbeek AM. In vivo depletion of CD4- and CD8-specific T cells. Curr Protoc Immunol Ed John E Coligan Al. 2001;Chapter 4:Unit 4.1.
24. Hochweller K, Striegler J, Hämmerling GJ, Garbi N. A novel CD11c.DTR transgenic mouse for depletion of dendritic cells reveals their requirement for homeostatic proliferation of natural killer cells. Eur J Immunol. 2008;38:2776-83.
25. Gorski KS, Waller EL, Bjornton-Severson J, Hanten JA, Riter CL, Kieper WC, Gorden KB, Miller JS, Vasilakos JP, Tomai MA, Alkan SS. Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists. Int Immunol. 2006;18:1115-26.
26. Shackleton M, Davis ID, Hopkins W, Jackson H, Dimopoulos N, Tai T, Chen Q, Parente P, Jefford M, Masterman K-A, Caron D, Chen W, Maraskovsky E, et al. The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand. Cancer Immun. 2004;4:9.
27. Horscroft NJ, Pryde DC, Bright H. Antiviral applications of Toll-like receptor agonists. J Antimicrob Chemother. 2012;67:789-801.
28. Kerr C. "Rub on" treatment for basal-cell carcinoma. Lancet Oncol. 2002;3:201.
29. Moon SD, Spencer JM. Clearance of invasive melanoma with topical imiquimod. J Drugs Dermatol JDD. 2013;12:107-8.
30. Dewan MZ, Vanpouille-Box C, Kawashima N, DiNapoli S, Babb JS, Formenti SC, Adams S, Demaria S. Synergy of topical toll-like receptor 7 agonist with radiation and low-dose cyclophosphamide in a mouse model of cutaneous breast cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2012;18:6668-78.
31. Naylor MF, Chen WR, Teague TK, Perry LA, Nordquist RE. In situ photoimmunotherapy: a tumour-directed treatment for melanoma. Br J Dermatol. 2006;155:1287-92.
32. Dovedi SJ, Melis MHM, Wilkinson RW, Adlard AL, Stratford IJ, Honeychurch J, Illidge TM. Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma. Blood. 2013;121:251-9.
33. Adlard AL, Dovedi SJ, Telfer BA, Koga-Yamakawa E, Pollard C, Honeychurch J, Illidge TM, Murata M, Robinson DT, Jewsbury PJ, Wilkinson RW, Stratford IJ. A novel systemically administered toll-like receptor 7 agonist potentiates the effect of ionizing radiation in murine solid tumor models. Int J Cancer J Int Cancer. 2014;
34. Kiessling R, Klein E, Wigzell H. "Natural" killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol. 1975;5:112-7.
35. Hoechst B, Ormandy LA, Ballmaier M, Lehner F, Krüger C, Manns MP, Greten TF, Korangy F. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology. 2008;135:234-43.
36. Koch M, Beckhove P, Op den Winkel J, Autenrieth D, Wagner P, Nummer D, Specht S, Antolovic D, Galindo L, Schmitz-Winnenthal FH, Schirrmacher V, Büchler MW, Weitz J. Tumor infiltrating T lymphocytes in colorectal cancer: Tumor-selective activation and cytotoxic activity in situ. Ann Surg. 2006;244:986-992; discussion 992-993.